Browsed by
Author: Member Success

Fzata Winner of Mid-Atlantic Innovation Celebration, Biotechnology

Fzata Winner of Mid-Atlantic Innovation Celebration, Biotechnology

Fzata, Inc., a biotech innovator, is proud to announce that it has been named the winner of the 2022 Mid-Atlantic Innovation Celebration for Biotechnology for its oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. The Company is honored to have been selected for this award from among so many highly innovative competitors. ...  Read more

MIMETAS expanded its license to the HUB Organoid Technology to include all organs – Drug Discovery & Development

MIMETAS expanded its license to the HUB Organoid Technology to include all organs – Drug Discovery & Development

MIMETAS, a global leader in Organ-on-a-Chip models and technology and headquartered in the Netherlands (Europe), announces  that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells. ...  Read more

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Chimerix, Inc. (NASDAQ: CMRX), to acquire Chimerix’s exclusive worldwide rights to TEMBEXA® (brincidofovir), the first antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. ...  Read more